London, United Kingdom (CU)_ An affiliate of Serum Institute of India has partnered with A Wockhardt company to establish a new vaccine production plant in Wrexham, North Wales in the UK. According to reports, the partnership between Wockhardt UK and Serum Life Sciences UK Ltd will…..Read More
contribute to the development of a significant number of new jobs as well as the establishment of a new sterile fill and finish facility in Wrexham, North Wales.
The two companies have agreed to share profits from this new production plant, which will produce an additional 150 million doses of various vaccines. Habil Khorakiwala, Chairman of Wockhardt, expressed optimism over the partnership. He said, “This collaboration between Serum Life Sciences and Wockhardt UK is testament to the excellence and innovation that both parties bring to the global vaccine market”.
According to Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt, the contract demonstrates the company’s expanded involvement in the global supply of numerous vaccines that safeguard populations against infectious illnesses including those used to immunize against COVID-19. Wockhardt UK teamed up with the UK government and AstraZeneca to develop a COVID-19 vaccine. The business claimed that its relationship with Serum Life Sciences is a continuation of a previous arrangement.
Natasha Poonawalla, Chairperson of Serum Life Sciences, expressed hopes over the collaboration. She said, “The collaboration will be instrumental in building long-term capacity in the UK. With this, we seek to further bolster supply resilience and support the global rollout of vaccines”.
